Bruker Corporation（BRKR）資訊與事件BRKRBruker Corporation

Bruker Releases Draft Atlas of Human Plasma Proteome

Bruker announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charite - Universitatsmedizin Berlin and collaborators. The atlas reveals extensive proteoform diversity among abundant plasma proteins involved in molecular transport, complement activity and coagulation. It provides a framework for understanding why protein measurements by affinity and mass spec-based proteomics technologies diverge, particularly for low-abundance proteins and for proteins occurring in many molecular isoforms

Bruker Corporation Unveils New Protein Analysis Workflows

At the Human Proteome Organization World Congress 2026, Bruker Corporation announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF discovery with prm-PASEF target validation on the same timsTOF platform. Novel timsOmni and integrated HDX-MS workflows extend structural analysis to glycopeptides, proteins, and nucleic acids. "We are combining proteome depth, PTMs, proteoforms, protein interactions, and conformational and spatial context to enable richer multimodal training data for next-generation biological AI models," said Frank Laukien, CEO. "These complementary molecular dimensions can extend existing models for drug discovery and mechanisms of action with information closely linked to biological function, helping advance molecular medicine more rapidly in the post-genomic era."